Advertisement Pharming acquires exclusive rights to Advanced Cell's transgenic technology - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Pharming acquires exclusive rights to Advanced Cell’s transgenic technology

Pharming Group has concluded a license agreement with Advanced Cell Technology to obtain exclusive rights on patents in the field of transgenic technology, to which it already had non-exclusive rights.

These patents were previously owned by Infigen and cover a wide range of technologies including for Pharming relevant elements of nuclear transfer, which is an essential step in generating transgenic cattle.

The agreement provides Pharming strict control over the generation of its transgenic cattle, while, at the same time, increasing the barriers of entry for others.